Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, they say “could be to prostate cancer what HER2 has become for breast cancer.”
Like HER2, they say in a press release, SPINK1 occurs in only a small subset of prostate cancers – about 10 percent. “But the gene is an ideal target for a monoclonal antibody, the same type of drug as Herceptin, which is aimed at HER2 and has dramatically improved treatment for this aggressive type of breast cancer.”
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet.
A genetic variant associated with aggressive prostate cancer has been discovered by researchers at Wake Forest University Baptist Medical Center. Claiming their discovery as a “first,” the scientists say that one day genetic information may be used in combination with other factors to guide treatment decisions.
Cancer May Lower HDL Cholesterol, Study Finds
Cancer may lower good, HDL cholesterol and low total cholesterol may be a sign of undiagnosed cancer, a long-running study following nearly thirty thousand men for almost 20 years has discovered. A related study suggests that lowering total cholesterol may help men reduce risk of high-grade prostate cancer.
Men with low cholesterol face less risk of high-grade prostate cancer
Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer — an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study.
Shorter Radiation Course Stops Cancer Growth in High-risk Prostate Cancer Patients
Hypofractionated radiation treatment, a newer type of radiation treatment that delivers higher doses of radiation in fewer treatments than conventional radiation therapy, is significantly more effective than the older method in stopping cancer growth in high risk patients and causes no increase in negative side effects, an Italian clinical trial shows.
Short Course High-Dose Radiation (IMRT) Looks Safe and Effective for Higher-Risk Prostate Cancer
ASTRO – A shorter, 5-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears just as effective and as safe for moderate and higher risk prostate cancer as standard radiation therapy, yet is delivered in two-and-a-half weeks less time.
Shorter and Safer Hospital Stays But More Risk of Incontinence and Erectile Dysfunction, Study Shows
New research indicates that the use of minimally invasive procedures (including the use of robotic assistance) for radical prostatectomy, which have increased significantly in recent years, may shorten hospital stays and decrease respiratory and surgical complications, but may also result in an increased rate of certain complications, including incontinence and erectile dysfunction, according to a study in the October 14 issue of JAMA
Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
NSAID Made No Difference to Cancer Growth
To see whether Celebrex (celecoxib) can reduce prostate cancer size and spread, a team from several leading US cancer centers led by Dr. Alan Partin and Dr. Michael Carducci conducted a randomized, double-blind trial enrolling high-risk men before primary treatment with surgery or radiation. They measured the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy on these men.